TrialAnnals of the rheumatic diseases2023

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.

Shaozhe Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.